Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm

References

• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• OvcharenkoSIChronic obstructive pulmonary disease: actual situation in Russia and ways to solve the problemPulmonology2011266972
   Google Scholar
• LandisSHMuellerovaHManninoDMContinuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
   PubMed Web of Science ®Google Scholar
• ChuchalinAGKhaltaevNAntonovNSChronic respiratory diseases and risk factors in 12 regions of the Russian FederationInt J Chron Obstruct Pulmon Dis2014996397425246783
   PubMed Web of Science ®Google Scholar
• ArtyukhovIPArshukovaILDobretsovaEADuginaTAShulminAVDemkoIVEpidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, RussiaInt J Chron Obstruct Pulmon Dis2015101781178626366070
   PubMed Web of Science ®Google Scholar
• World Health OrganizationNMH/MND/CPM/13.1. Global alliance against chronic respiratory diseases (GARD)7th General Meeting9–10 July 2012St. Petersburg, RussiaGenevaWorld Health Organization2013 Available from: http://www.who.int/gard/publications/GARDG-MReportStPetersburg2012.pdfAccessed February 9, 2017
   Google Scholar
• RabeKFHurdSAnzuetoAGlobal Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2007176653255517507545
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDECLIPSE InvestigatorsChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• JonesPWHealth status and the spiral of declineCOPD200961596319229709
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)global strategy for the diagnosis, management and prevention of COPD2016 http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/Accessed February 9, 2017
   Google Scholar
• HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
   PubMed Web of Science ®Google Scholar
• Federal clinical recommendations for diagnostics and treatment of chronic obstructive pulmonary diseaseRussian Respiratory Society2014 Available from: http://pulmonology.ru/download/COPD2014may2.docAccessed February 9, 2017 Russian
   Google Scholar
• The Japanese Respiratory SocietyGuidelines for the Diagnosis and Treatment of COPD4th edTokyoJapanese Respiratory Society2013
   Google Scholar
• HizawaNLAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypesInt J Chron Obstruct Pulmon Dis2015101093110226089659
   PubMed Web of Science ®Google Scholar
• CooperCBBarjaktarevicIA new algorithm for the management of COPDLancet Respir Med20153426626825890644
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a pre-specified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• PriceDBBakerCLZouKHHigginsVSBaileyJTPikeJSReal-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classificationInt J Chron Obstruct Pulmon Dis2014955156124920893
   PubMed Web of Science ®Google Scholar
• JonesPTabbererMChenWHCreating scenarios of the impact of COPD and their relationship to COPD assessment test (CAT™) scoresBMC Pulm Med2011114221835018
   PubMed Web of Science ®Google Scholar
• JonesPWAdamekLNadeauGBanikNComparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classificationEur Respir J201342364765423258783
   PubMed Web of Science ®Google Scholar
• ChettaAOlivieriDThe COPD Assessment Test in the evaluation of chronic obstructive pulmonary disease exacerbationsExpert Rev Respir Med20126437337522971062
   PubMed Web of Science ®Google Scholar
• KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• KesslerRStåhlEVogelmeierCPatient understanding, detection, and experience of COPD exacerbations: an observational, interview-based studyChest2006130113314216840393
   PubMed Web of Science ®Google Scholar
• SpencerSCalverleyPMBurgePSJonesPWImpact of preventing exacerbations on deterioration of health status in COPDEur Respir J200423569870215176682
   PubMed Web of Science ®Google Scholar
• ZhangRTanXHeQComparison of symptom and risk assessment methods among patients with chronic obstructive pulmonary diseaseChin Med J (Engl)2014127142594259825043073
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSRodriguez-RoisinRThe 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)–why and what?Clin Respir J20126420821422906068
   PubMed Web of Science ®Google Scholar
• RocaMVerduriACorbettaLCliniEFabbriLMBeghéBMechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary diseaseEur J Clin Invest201343551052123489139
   PubMed Web of Science ®Google Scholar
• LeidyNKMurrayLTMonzBUMeasuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trialsRespir Res20141512425287629
   PubMed Web of Science ®Google Scholar
• ZoorobRGrigoryanLNashSTrautnerBWNonprescription antimicrobial use in a primary care population in the United StatesAntimicrob Agents Chemother20166095527553227401572
   PubMed Web of Science ®Google Scholar
• LlorCMonnetDCotsJSmall pharmacies are more likely to dispense antibiotics without a medical prescription than large pharmacies in Catalonia, SpainEuro Surveill20101532
   Google Scholar
• ChangJYeDLvBSale of antibiotics without a prescription at community pharmacies in urban China: a multicentre cross-sectional surveyJ Antimicrob Chemother Epub201716
   Web of Science ®Google Scholar
• LaueJMelbyeHHalvorsenPAHow do general practitioners implement decision-making regarding COPD patients with exacerbations? An international focus group studyInt J Chron Obstruct Pulmon Dis2016113109311927994450
   PubMed Web of Science ®Google Scholar
• BeghéBVerduriARocaMFabbriLMExacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPDEur Respir J201341499399523543648
   PubMed Web of Science ®Google Scholar
• LeeSDHuangMSKangJInvestigators of the Predictive Ability of CAT in Acute Exacerbations of COPD (PACE) StudyThe COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patientsRespir Med2014108460060824456695
   PubMed Web of Science ®Google Scholar
• MackayAJDonaldsonGCPatelARJonesPWHurstJRWedzichaJAUsefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbationsAm J Respir Crit Care Med2012185111218122422281834
   PubMed Web of Science ®Google Scholar
• TuYHZhangYFeiGHUtility of the CAT in the therapy assessment of COPD exacerbations in ChinaBMC Pulm Med2014144224618290
   PubMed Web of Science ®Google Scholar
• SinghDZhuCQSharmaSChurchAKalbergCJDaily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover studyPulm Pharmacol Ther201531859125197005
   PubMed Web of Science ®Google Scholar
• CazzolaMSantusPD’AddaAPizzolatoSDi MarcoFCentanniSAcute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPDPulm Pharmacol Ther200922317718219038356
   PubMed Web of Science ®Google Scholar
• ColeJMSheehanAHJordanJKConcomitant use of ipratropium and tiotropium in chronic obstructive pulmonary diseaseAnn Pharmacother201246121717172123170031
   PubMed Web of Science ®Google Scholar
• HalpinDMDahlRHallmannCMuellerATashkinDTiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysisInt J Chron Obstruct Pulmon Dis20151023925925709423
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlRINVIGORATE investigatorsOnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• MahlerDAKerstjensHADonohueJFBuhlRLawrenceDAltmanPIndacaterol vs tiotropium in COPD patients classified as GOLD A and BRespir Med201510981031103926094050
   PubMed Web of Science ®Google Scholar
• Al-ShowairRATarsinWYAssiKHPearsonSBChrystynHCan all patients with COPD use the correct inhalation flow with all inhalers and does training help?Respir Med2007101112395240117629471
   PubMed Web of Science ®Google Scholar
• SriramKBPercivalMSuboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patientsChron Respir Dis2016131132226396159
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• MahlerDAKerwinEAyersTFLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201519291068107926177074
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBEFormoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study GroupComparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• MakinoSAdachiMOhtaKSafety of Sustained-Release Theophylline and Injectable Methylxanthines CommitteeAsthma Prevention and Management Guidelines CommitteeA prospective survey on safety of sustained-release theophylline in treatment of asthma and COPDAllergol Int200655439540217130682
   PubMedGoogle Scholar
• FexerJDonnachieESchneiderAThe effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management programDtsch Arztebl Int20141111729330024828099
   PubMed Web of Science ®Google Scholar
• BeldaJLeighRParameswaranKO’ByrnePMSearsMRHargreaveFEInduced sputum cell counts in healthy adultsAm J Respir Crit Care Med20001612 Pt 147547810673188
   PubMed Web of Science ®Google Scholar
• GaoPZhangJHeXHaoYWangKGibsonPGSputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary diseasePLoS One201385e5767823741289
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• AlbertRKConnettJBaileyWCCOPD Clinical Research NetworkAzithromycin for prevention of exacerbations of COPDN Engl J Med2011365868969821864166
   PubMed Web of Science ®Google Scholar
• ZykovKRvatchevaAPustovalovAAveryanovALong-term treatment with clarithromycin of stage II COPD patients with frequent exacerbationsEur Respir J200832Suppl 521770
   Google Scholar
• ZhengJPKangJHuangSGEffect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled studyLancet200837196292013201818555912
   PubMed Web of Science ®Google Scholar
• TseHRaiteriLWongKYNgLYYeeKSTsengCZBenefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPDChest2014146361162324833327
   PubMed Web of Science ®Google Scholar
• DasguptaANeighbourHNairPTargeted therapy of bronchitis in obstructive airway diseasesPharmacol Ther2013140321322223845862
   PubMed Web of Science ®Google Scholar
• MoritzPSteidleLJFelisbinoMBKlevestonTPizzichiniMMPizzichiniEDetermination of the inflammatory component of airway diseases by induced sputum cell counts: use in clinical practiceJ Bras Pneumol2008341191392119099097
   PubMedGoogle Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• SivaRGreenRHBrightlingCEEosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trialEur Respir J200729590691317301099
   PubMed Web of Science ®Google Scholar
• SinghDKolsumUBrightlingCELocantoreNAgustiATal-SingerRECLIPSE investigatorsEosinophilic inflammation in COPD: prevalence and clinical characteristicsEur Respir J20144461697170025323230
   PubMed Web of Science ®Google Scholar
• PavordIDBafadhelMExhaled nitric oxide and blood eosinophilia: independent markers of preventable riskJ Allergy Clin Immunol2013132482882924001802
   PubMed Web of Science ®Google Scholar
• NegewoNAMcDonaldVMBainesKJPeripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPDInt J Chron Obstruct Pulmon Dis2016111495150427445469
   PubMed Web of Science ®Google Scholar